Amylyx to present LUCIDITY Phase 3 avexitide topline data at ObesityWeek 2026 on Nov. 15

Amylyx says it will present Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia in a late-breaking oral session set for Nov. 15, 2026, in Washington, D.C., after prior disclosed positive topline results.